

# PRELIMINARY TIMETABLE

# ECIO 2024

APRIL 28 – MAY 1  
PALMA DE MALLORCA, SPAIN

SUNDAY, APRIL 28

MONDAY, APRIL 29

TUESDAY, APRIL 30

WEDNESDAY, MAY 1

Auditorium 1	Auditorium 2	Auditorium 3	Hands-on TA	Hands-on SED/MSK/RE	Auditorium 1	Auditorium 2	Auditorium 3	Hands-on TA	Hands-on SED/MSK/RE	Auditorium 1	Auditorium 2	Auditorium 3	Hands-on TA	Hands-on SED/MSK/RE	Auditorium 2	Auditorium 3	
<div>CF 111</div> <div>Combination strategies in the management of HCC</div>	<div>CF 112</div> <div>Cancer as a chronic disease</div>		<div>HDT-TA 11.1</div> <div>Tumour ablation: cold based ablation</div>		<div>CF 211</div> <div>Colorectal cancer liver metastases</div>	<div>CF 212</div> <div>Paediatric IO: a practical approach</div>	<div>CF 213</div> <div>Pain and gain: communication skills</div>	<div>HDT-TA 21.1</div> <div>Tumour ablation: heat based ablation</div>	<div>SED 21.2</div> <div>Safe sedation application during IR procedures (basic)</div>	<div>CF 311</div> <div>Open debates in modern HCC treatment</div>	<div>CF 312</div> <div>MSK IO: ablate, palliate and protect</div>	<div>CF 313</div> <div>Access to IO in Europe</div>	<div>HDT-TA 31.1</div> <div>Tumour ablation: planning, robotics, monitoring and assessment for ablation</div>	<div>HDT-RE 31.2</div> <div>Radioembolization: dosimetry and administration systems</div>	<div>TB 411</div> <div>Why an IO should be on the tumour board: metastatic colorectal cancer</div>	<div>CF 412</div> <div>Bleeding emergencies in cancer patients</div>	
<div>CF 121</div> <div>Immuno oncology: on the delicate interaction of local treatment and systemic immunologic effects</div>	<div>CF 122</div> <div>Bone metastases: multidisciplinary management</div>		<div>HDT-TA 12.1</div> <div>Tumour ablation: heat based ablation</div>	<div>SED 12.2</div> <div>Safe sedation application during IR procedures (basic)</div>	<div>HL 221</div> <div>Honorary Lecture</div>			<div>HDT-TA 22.1</div> <div>Tumour ablation: planning, robotics, monitoring and assessment for ablation</div>	<div>SED 22.2</div> <div>Safe sedation application during IR procedures (advanced)</div>	<div>TB 321</div> <div>Why an IO should be on the tumour board: renal cancer</div>	<div>CF 322</div> <div>Artificial intelligence for interventional oncology</div>	<div>SP 323</div> <div>Technical developments and clinical results in the treatment of liver tumours</div>	<div>HDT-TA 32.1</div> <div>Tumour ablation: non thermal ablation</div>	<div>HDT-MSK 32.2</div> <div>Musculoskeletal oncologic interventions</div>	<div>MM 421</div> <div>Morbidity &amp; Mortality</div>		
	<div>SY 131</div> <div>Satellite Symposium</div>			<div>SED 13.1</div> <div>Safe sedation application during IR procedures (basic)</div>		<div>SY 231</div> <div>Satellite Symposium</div>			<div>SED 23.1</div> <div>Safe sedation application during IR procedures (Propofol)</div>		<div>SY 331</div> <div>Satellite Symposium</div>				<div>CF:</div> <div>Clinical Focus Session</div>	<div>livestreamed</div>	
	<div>SY 132</div> <div>Satellite Symposium</div>					<div>SY 232</div> <div>Satellite Symposium</div>					<div>SY 332</div> <div>Satellite Symposium</div>				<div>TF:</div> <div>Technical Focus Session</div>		
	<div>SY 133</div> <div>Satellite Symposium</div>					<div>SY 233 – Sat. Symp.</div>					<div>SY 333 – Sat. Symp.</div>				<div>VL:</div> <div>Video Learning Session</div>	<div>onsite exclusive</div>	
<div>TB 141</div> <div>Why an IO should be on the tumour board: HCC</div>	<div>CF 142</div> <div>Ask me anything</div>	<div>CF 143</div> <div>Meet the PI: upcoming research</div>	<div>HDT-TA 14.1</div> <div>Tumour ablation: non thermal ablation</div>	<div>SED 14.2</div> <div>Safe sedation application during IR procedures (advanced)</div>	<div>EM 241</div> <div>ECIO meets ESTRO</div>	<div>CF 242</div> <div>Non-small cell lung cancer in 2024</div>		<div>HDT-TA 24.1</div> <div>Tumour ablation: cold based ablation</div>	<div>HDT-RE 24.2</div> <div>Radioembolization: dosimetry and administration systems</div>	<div>CF 341</div> <div>Breast cancer: new scenarios for an old disease</div>	<div>EM 342</div> <div>ECIO meets ESOT</div>	<div>CF 343</div> <div>Targeting tumours and assessing the results of treatment</div>	<div>HDT-TA 34.1</div> <div>Tumour ablation: heat based ablation</div>	<div>HDT-MSK 34.2</div> <div>Musculoskeletal oncologic interventions</div>	<div>TB:</div> <div>Tumour Board</div>	<div>BC:</div> <div>Basic Course</div>	
<div>CF 151</div> <div>Intrahepatic cholangiocarcinoma: what IRs need to know?</div>	<div>CF 152</div> <div>Selecting my best first case: why, when, how</div>	<div>BC 153</div> <div>Basic Course: Kidney and adrenal: renal ablation basics 1</div>	<div>HDT-TA 15.1</div> <div>Tumour ablation: planning, robotics, monitoring and assessment for ablation</div>		<div>TB 251</div> <div>Why an IO should be on the tumour board: lung</div>	<div>CF 252</div> <div>Clinical studies and interventional oncology</div>	<div>BC 253</div> <div>Basic Course: Kidney and adrenal: renal ablation basics 2</div>	<div>HDT-TA 25.1</div> <div>Tumour ablation: non thermal ablation</div>		<div>VL 351</div> <div>How I do it – video learning</div>	<div>SP 352</div> <div>Extrahepatic application for IO: revisiting the old and embracing the new</div>	<div>BC 353</div> <div>Basic Course: Kidney and adrenal: adrenal ablation</div>	<div>HDT-TA 35.1</div> <div>Tumour ablation: cold based ablation</div>		<div>SP:</div> <div>Scientific Paper Session</div>	<div>EBIR:</div> <div>Morbidity and Mortality</div>	
	<div>SY 160 – Sat. Symp.</div>														All times are shown in CEST		
																© Cardiovascular and Interventional Radiological Society of Europe / 2024. CIRSE does not accept responsibility for errors or misprints.	

As per March 2024